Últimas noticias sobre OS Therapies (AMEX:OSTX) Bolsa

OS Therapies

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.

OS Therapies Inc

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Westport Fuel Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) with a Buy and maintains $22 price target.

News

Price Target

Reiteration

Analyst Ratings

WPRT

HC Wainwright & Co. Reiterates Buy on Westport Fuel Systems, Maintains $22 Price Target

WIIM

Evotec shares are trading higher after Halozyme Therapeutics confirmed a cobmination offer.

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Aemetis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) with a Buy and maintains $28 price target.

AMTX

HC Wainwright & Co. Reiterates Buy on Aemetis, Maintains $28 Price Target

Trading Ideas

NFT Limited Shares Halted On Circuit Breaker To The Downside, Stock Now Down -62.9%

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling by more than 300 points on Friday.
The Dow traded down 0.78% to 43,410.32 while the NASDAQ fell 2.50% to 18,630.37. The S&amp;P 500 also fell, dropping, 1.51% to 5,859.61.
Check This Out: <a href="https://www.benzinga.com/24/11/42005109/top-4-utilities-stocks-that-may-keep-you-up-at-night-this-quarter">Top 4 Utilities Stocks That May Keep You Up At Night This Quarter</a>
Leading and Lagging Sectors Utilities shares rose by 1% on Friday.
In trading on Friday, information technology shares fell by 2.7%.
Top Headline
The total number of active U.S. oil rigs fell by one to 478 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>The Arena Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) shares shot up 181% to $1.63 after it announced its first ever profitable quarter.</li>
<li>Shares of Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) got a boost, surging 55% to $20.59 after the energy company became the latest to announce a major deal to power AI data centers. Bloom Energy announced Thursday evening that it has signed a supply agreement with American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) for up to 1 gigawatt (GW) of its products, the largest commercial procurement of fuel cells in the world to date.&nbsp;</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares were also up, gaining 46% to $1.29 after the company announced a $400,000 contract to supply autonomous cleaning robots at Singapore&#8217;s International Airport Terminal.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares dropped 77% to $0.37 after the company announced it will wind down its operations.</li>
<li>Shares of Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) were down 70% to $0.10 after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.</li>
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) was down, falling 26% to $1.26 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $67.20 while gold traded down 0.1% at $2,572.20.
Silver traded down 0.5% to $30.425 on Friday, while copper fell 0.5% to $4.0690.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.77%, Germany's DAX fell 0.27% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index gained 0.97%, while London's FTSE 100 fell 0.09%.
The annual inflation rate in Italy increased to 0.9% in October versus 0.7% in the prior month, while France&#8217;s annual inflation rate rose to 1.2% in October. The GDP in the UK grew by 1% year-over-year during the third quarter.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 gaining 0.28%, Hong Kong's Hang Seng Index falling 0.05% and China's Shanghai Composite Index dipping 1.45%.
Hong Kong's economy expanded by 1.8% year-over-year in the third quarter compared to a 3.2% increase in the previous period. China&#8217;s retail sales rose by 4.8% year-over-year in October, while industrial production rose by 5.3% year-over-year in October.
Economics
<ul>
<li>The NY Empire State Manufacturing Index surged to 31.2 in November versus -11.9 in the previous month and topping market estimates of -0.7.</li>
<li>U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October.</li>
<li>U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, and toping market estimates of 0.3%.</li>
<li>U.S. industrial production declined by 0.3% in October compared to a revised 0.5% declined in September.</li>
<li>The total number of active U.S. oil rigs fell by one to 478 rigs this week, Baker Hughes Inc reported.</li>
<li>U.S. business inventories rose 0.1% month-over-month in September compared to a 0.3% gain in August and versus market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42007351/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

Markets

AREN

EYEN

RVYL

SPPL

TFFP

Crude Oil Dips Over 2%; Bloom Energy Shares Spike Higher

Needham analyst Mike Matson reiterates Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and maintains $112 price target.

Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says Neutral Is Significantly Lower Than Where Fed Policy Rate Is Now; If Productivity Growth Stays Higher Than Trend, Need To Be Careful Relying On GDP Growth Rate To Check If Economy Is Overheating

<ul>
<li>Postal Service continues to offer a great value for shipping with our reliable service to the American people. &nbsp;</li>
<li>Pricing actions part of balanced approach under "Delivering for America," the Postal Service's 10-year plan for achieving financial sustainability and service excellence.</li>
<li>Rate changes will support the $40 billion of investments in people, technology, and infrastructure and continue the modernization and improvement of the Postal Service's operations and customer experience.</li>
<li>As we previously announced, the Postal Service will not be <a href="https://www.streetinsider.com/entities/Raising+Prices">raising prices</a> in January for our Mailing Services, therefore, the price of a First-Class stamp will remain unchanged.</li>
</ul>
WASHINGTON, Nov. 15, 2024 /PRNewswire/ -- Today, the Postal Service filed notice with the Postal Regulatory Commission (PRC) for Shipping Services price changes to take effect January 19, 2025. The proposed adjustments were approved by the Governors of the USPS this week.&nbsp;
The change would raise Shipping Services prices approximately 3.2 percent for Priority Mail service and Priority Mail Express service, 3.9 percent for USPS Ground Advantage and 9.2 percent for Parcel Select.
Although Mailing Services price increases are based on the consumer price index, Shipping Services prices are primarily adjusted according to market conditions. The governors believe these new rates will keep the Postal Service competitive while providing the agency with needed revenue. As we previously announced, the Postal Service will not be raising prices in January for our Mailing Services.
As a strategic part of the <a href="https://about.usps.com/what/strategic-plans/delivering-for-america/?_gl=1&#x2A;63lmng&#x2A;_ga&#x2A;MTU2OTA3OTA5MC4xNjU2NTIwNTUx&#x2A;_ga_3NXP3C8S9V&#x2A;MTY2NDk4ODA1NS40NDIuMS4xNjY0OTg4MDkyLjAuMC4w">Delivering for America</a> 10-year plan, these proposed changes will support the Postal Service in creating a revitalized organization capable of achieving our public service mission — providing a nationwide, integrated network for the delivery of mail and packages at least six days a week — in a cost-effective and financially sustainable manner over the long term, just as the U.S. Congress has intended.&nbsp;
The PRC will review the changes before they are scheduled to take effect. The complete Postal Service price filing, with prices for all products, can be found on the PRC website under the Daily Listings section at <a href="https://prc.arkcase.com/portal/docket-search/daily-listings">prc.gov/dockets/daily</a>. The Mailing Services filing is Docket No. CP2025-1. The price tables are also available on the Postal Service's Postal Explorer website at <a href="https://pe.usps.com/PriceChange/Index">pe.usps.com/PriceChange/Index</a>.

U.S. Postal Service Recommends New Competitive Prices For 2025; Will Not Be Raising Prices In Jan For Mailing Services; Price Of First-Class Stamp To Remain Unchanged; Change Would Raise Shipping Services Prices About 3.2% For Priority Mail Service And Priority Mail Express Service; Change Would Raise Shipping Services Prices 3.9% For USPS Ground Advantage & 9.2% For Parcel Select

Needham analyst Mayank Tandon maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $245 to $265.

GLOB

Needham Maintains Buy on Globant, Raises Price Target to $265

HALO

Halozyme Therapeutics shares are trading lower after the company announced a proposal to combine with Evotec.

HC Wainwright &amp; Co. analyst Edward White reiterates InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) with a Buy and maintains $8 price target.

IFRX

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

Bancorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NYSE">TBBK</a>) short percent of float has fallen 3.81% since its last report. The company recently reported that it has 6.48 million shares sold short, which is 17.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Bancorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731698129_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bancorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Bancorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Bancorp's peer group average for short interest as a percentage of float is 4.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

TBBK

How Is The Market Feeling About Bancorp?

SPS Commerce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NYSE">SPSC</a>) short percent of float has risen 3.94% since its last report. The company recently reported that it has 719 thousand shares sold short, which is 2.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SPS Commerce Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731698124_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SPS Commerce has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SPS Commerce's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SPS Commerce's peer group average for short interest as a percentage of float is 8.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SPSC

Looking Into SPS Commerce's Recent Short Interest

Monday.Com's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NYSE">MNDY</a>) short percent of float has risen 4.31% since its last report. The company recently reported that it has 2.71 million shares sold short, which is 6.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Monday.Com Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731698119_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monday.Com has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Monday.Com's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Monday.Com's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MNDY

Looking Into Monday.Com's Recent Short Interest

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

ATNM

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

On Friday, Gilead Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42012386/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety-profile-in-mana" rel="noreferrer noopener">efficacy and safety of Livdelzi</a>.
The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi&nbsp;(seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression.
Additionally, 41% (15 out of 37) of participants achieved normalization of alkaline phosphatase (ALP) levels, a critical biomarker of liver function.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook</a>
Livdelzi continues to appear generally well tolerated, with no new safety signals or change in frequency of adverse events (AEs) with up to three years of exposure.
In August, the FDA granted accelerated approval for&nbsp;Gilead&#8217;s Livdelzi&nbsp;for primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA or as monotherapy in patients&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal" rel="noreferrer noopener">unable to tolerate UDCA</a>.
In addition to the ASSURE data, Gilead showcased findings from two oral presentations highlighting additional analyses from the Phase 3 RESPONSE trial:
<ul>
<li>At Month 12, the adjusted mean change from baseline in ALP for participants with cirrhosis on Livdelzi was -121.4 U/L (a decrease of approximately 35% from baseline) versus 23.2 U/L (an increase of approximately 6.6%) on placebo.</li>
<li>-134.8 U/L (down 43.5%) for Livdelzi versus -18.0 U/L (a decrease of approximately 5.8%) for placebo in participants without cirrhosis.</li>
<li>A secondary analysis of pruritus in RESPONSE showed that among participants with a numerical rating score (NRS) of ≥4 and NRS ≥7 at baseline, Livdelzi led to near resolution (NRS of 0 or 1) of itch at Month 12 in 26.5% and 18.8% of participants, respectively, versus 0% of participants on placebo.</li>
</ul>
Price Action: GILD stock is down 3.48% at $88.90 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/24/11/42003337/trumps-victory-spurs-50b-corporate-bond-surge-as-tax-cut-optimism-drives-borrowing-costs-to-25-year-low" target="_blank" rel="noreferrer noopener">Trump&#8217;s Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low</a></li>
</ul>

Biotech

Equities

Large Cap

Health Care

Movers

General

GILD

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Wells Fargo analyst Ike Boruchow maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Overweight and raises the price target from $65 to $75.

Wells Fargo Maintains Overweight on Tapestry, Raises Price Target to $75

HC Wainwright &amp; Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and maintains $22 price target.

YMAB

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) with a Overweight and lowers the price target from $20 to $12.

CABA

Wells Fargo Maintains Overweight on Cabaletta Bio, Lowers Price Target to $12

The recent U.S. presidential election results, including a Republican sweep, have raised questions about the future of renewable energy under President-elect Donald Trump&#8217;s leadership.
Morgan Stanley&#8217;s report evaluates the economic impact on renewables under various policy scenarios and its effects on earnings.
The analyst has adjusted its view on the clean tech industry to &#8220;In-Line&#8221; from &#8220;Attractive.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41880110/solar-renewables-stocks-crash-after-trump-win-should-you-buy-now-at-cheap-valuations" rel="noreferrer noopener">Solar, Renewables Stocks Crash After Trump Win: Should You Buy Now At Cheap Valuations?</a>
While long-term demand for renewables is likely stronger than current market perceptions, near-term growth prospects have become less clear due to new uncertainties.
It&#8217;s important to remember that these new uncertainties add to the already difficult environment facing the clean energy sector, dealing with issues such as permitting and interconnection delays, funding challenges, and intense competition that have hurt profitability.
Uncertainty about the Inflation Reduction Act (IRA), tariffs, and interest rates has significantly impacted clean fuel valuations.
Morgan Stanley writes that clear guidance on the IRA is essential for clean tech valuations to rebound. However, this may take time since it will likely be linked to discussions about the Tax Cuts and Job Act&nbsp;(TCJA), which is set to expire at the end of 2025.
Morgan Stanley recommends investing in stocks with high-quality and durable growth/ margins, with a clear catalyst path and/or strong balance sheet to weather any near-term volatility in growth and/or profitability.
<ul>
<li>The analyst maintains an Overweight rating on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), and Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>).</li>
</ul>
However, the analyst has downgraded three cleantech stocks from Equal-weight to Underweight, including:
<ul>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>): The analyst reduced the price target from $23 to $9, citing slower profitability due to decreased European demand and tough competition from cheaper Chinese manufacturers. As a result, the company is not expected to break even on <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings" target="_blank" rel="noreferrer noopener">EBITDA until after 2026</a>. At last check Friday, the stock was trading 13.2% lower at $11.13.</li>
<li>Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>): Morgan Stanley anticipates a slow recovery to profitability due to increasing competition in Europe&#8217;s utility-scale solar market, which will likely keep pushing prices down. The analyst maintains the <a href="https://www.benzinga.com/quote/MAXN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $4</a>. Additionally, recent customer losses in the U.S. residential market could make maintaining market share and premium pricing harder. Stock is trading 10.08% lower at $10.08 at last check Friday.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>): The analyst notes an uncertainty about how quickly the U.S. wind market will recover, mainly due to challenges in securing financing and recent issues with design and inspections as the industry shifts to larger blade sizes. Morgan Stanley has cut the <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $4 to $2</a>. Stock is down 8.82% at $2.16 at the last check Friday.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42012689/life-insurance-firm-aegon-trades-higher-as-capital-ratios-remain-solid" target="_blank" rel="noreferrer noopener">Life Insurance Firm Aegon Trades Higher As Capital Ratios&#8217; Remain Solid&#8217;</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Government

Downgrades

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

SEDG

TPIC

Trump's Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OS Therapies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ostx-stock-quote/">OSTX</a>) just reported results for the second quarter of 2024.<ul><li>OS Therapies reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/ostx-stock-earnings-os-therapies-for-q2-of-2024/">OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024

Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting

Meeting to be held with President & CEO Romness and CBO Commissiong on November 6 hosted by Maxim. Published first on TheFly – the ultimate source ...

OS Therapies management to meet with Maxim

This prospectus relates to the resale from time to time by Square Gate Capital Master Fund of OS Therapies (OSTX)' shares of common stock, in an of...

OS Therapies files to sell $15M in common stock for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OS Therapies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ostx-stock-quote/">OSTX</a>) just reported results for the second quarter of 2024.<ul><li>OS Therapies reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/ostx-stock-earnings-os-therapies-for-q2-of-2024/">OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AAPL

AMZN

BMEA

CHTR

DASH

FFIV

FVRR

GOOG

HSBC

IDCC

INTC

INUV

LFVN

LMND

MGPI

MRNS

MSFT

OSTX

PAPL

PHUN

PTON

QRVO

RDDT

RKLB

RMLFF

SABR

SAVE

SBUX

SNAP

SVCO

TLTFF

UBER

WHLR

XPEV

Press Releases

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies to Present at The Spartan Capital Investor Conference

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

OS Therapies

Noticias

Últimas noticias sobre OS Therapies (AMEX:OSTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL